Neurim Pharmaceuticals initiates Phase III study of Paediatric Prolonged-Release Melatonin in children with Autistic Spectrum Disorders, suffering from sleep disturbances


  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
    • Neurim sponsors a Satellite Symposium “Navigating through the Insomnia Roadmap in Children with ASD” at IPSA 2018, Paris, France.
    • Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by BIOCODEX Oy in Finland
  • Partners

    Partners